Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.

Abstract: The present invention provides p53 proteins with altered tetramerization domains that retain wild-type p53 function, and the ability to form tetramers and have at least one of the following characteristics: (1) do not hetero-oligomerize with wild-type p53 or tumor-derived p53 mutants, and (2) restricted DNA binding specificity from an alteration in the way that the tetramerization domain orients the DNA binding domains of a p53 tetramer relative to one another. The invention also provides nucleic acids encoding the above proteins and methods of enhancing the cellular response to DNA damaging agents, treating diseases characterized by abnormal cell proliferation, and inducing immune tolerance to facilitate transplants and treatment of autoimmune disease, by administration of proteins of the invention or nucleic acid sequences encoding the proteins of the invention.

Abstract: The present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle. The vaccine can be administered in two different forms: (1) cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus or (2) an O polysaccharide antigen deficient, stable transposon mutant of B. abortus.

Abstract: Phosvitin or a modified phosvitin immobilised and coupled to a suitable matrix may be used for the separation and purification of proteins or polypeptides and in the removal of metal ions from biological material. If desired the phosvitin or modified phosvitin may be in the form of a metal chelate complex.

Abstract: Novel assays for identifying agents which alter the effect of erythropoietin on proliferation of erythroid cells and agents identified thereby. Novel peptide comprising the erythropoietin receptor binding site for SH-PTP1.

Abstract: A purified protein that is identified herein as insulin receptor substrate 1 (IRS-1) is disclosed, as well as a method of purifying IRS-1 and a recombinant nucleic acid encoding it.

Abstract: The subject invention provides for nucleotide sequences encoding polypeptide p62 and derivatives thereof. Another aspect of the subject invention also provides for methods of purifying p62 and derivatives thereof from cells naturally producing p62 and from cells genetically modified so as to produce p62.The subject invention also provides for methods of assaying tyrosine kinase activity by means of measuring the phosphorylation of p62 and p62 derivatives. Measurement of p62/p62 derivative phosphorylation may be used to determine whether or not a call is cancerous.

Abstract: A conjugate of an antiviral nucleoside with a lactosaminated human albumin (L-HSA) and its method of preparation is described. The method of preparation involves the reaction of an antiviral phosphorylated nucleoside in the form of an imidizolide with L-HSA at a pH above 7.5 and running the reaction until the desired molar ratio of drug to L-HSA is obtained.

Abstract: Methods and compositions useful in the detection of human cancer cells and malignant tumors are provided. Certain human autocrine motility factor receptors or proteins (gp78-hAMFR) have been identified which are useful in the detection of human cancer cells and malignant tumors. Methods and assay kits for the detection of human cancer, human cancer cells, and tumors, are provided wherein antibodies or other probes are used which recognize gp78-hAMFR expression. These methods and assay readily distinguish between non-malignant and malignant cancer cells and tumors and can be used to gauge metastatic potential.

Abstract: A method of treating solid tumor cancer in a living being by prolonging the time a therapeutically effective agent remains in the tumor. The method comprises the steps of selecting particles of an aggregated protein and injecting them interstitially into the tumor. The therapeutically effective agent selected from the group consisting of radioactive antibodies and radioactive growth factors is injected into the tumor either after the injection of the proteinaceous particles, or simultaneously.

Abstract: A self-supporting composite bioactive material and method of making it, which comprises immersing a body of collagen in a solution comprising a calcium phosphate and a phosphoprotein (preferably containing o-phosphoserine residues) to deposit on the collagen a mineralized layer of calcium phosphate and the phosphoprotein.

Abstract: Described are derivatives of the precursor peptide of the cardiodilatin/atrial sodiuretic factor (CDD-ANF) or fragments thereof which comprise at least the amino acid sequence of alpha-hANaP. The derivatives according to the present invention are compounds of the formula (I) ##STR1## X is a phosphate or thiophosphate group. R is NH.sub.2 or a peptide fragment from the amino acid sequence of gamma-hANaP. Radio-labelled derivatives are also possible. A method for the qualitative and/or quantitative determination of peptides containing the sequence of alpha-hANaP and a use of the compounds having the formula (I) as medicaments for various vaso- and renal related disorders are further described.

Abstract: The-invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.

Abstract: A method for assaying a medium for the presence of a substance that affects an SH2-phosphorylated ligand regulatory system. The method employs an SH2-like domain or a subdomain thereof and a phosphorylated ligand. The phosphophorylated ligand is capable of interacting with the SH2-like domain or a subdomain thereof to form an SH2-phosphorylated ligand complex. The SH2-like domain or subdomain and/or the phosphorylated ligand are present in a known concentration. The SH2-like domain or a subdomain thereof and the phosphorylated ligand are incubated with a substance which is suspected of affecting an SH2-phosphorylated ligand regulatory system. The method is carried out under conditions which permit the formation of the SH2-phosphorylated ligand complex. SH2-phosphorylated ligand complex, free SH2-like domain or subdomains thereof, or non-complexed phosphorylated ligand are assayed.

Abstract: Non-phosphorylated peptides and phosphopeptides useful as alimentary products or medicaments are produced by proteolytic enzyme hydrolysis of a casein-based material. Membrane ultrafiltration is used to separate phosphopeptides which are retained by the membrane in a retentate from the non-phosphorylated peptides which pass through the membrane in an ultrafiltrate. The phosphopeptides in the retentate are disaggregated and are subjected to further membrane ultrafiltration where the phosphopeptides pass through the membrane and are separated from the enzyme. The non-phosphorylated peptides have nutritive value and can be used to form compositions for providing nutrition. The phosphopeptides form salts, which have dietetic uses, with macroelements such as calcium and/or magnesium and/or oligoelements such as iron and zinc.

Abstract: Non-phosphorylated peptides and phosphopeptides useful as alimentary products or medicaments are produced. A hydrolyzate containing non-phosphorylated peptides and phosphopeptides is prepared by proteolytic enzyme hydrolysis of a casein-based material. The hydrolyzate is subjected to ultrafiltration with a membrane which allows peptides to pass through to produce a permeate containing the non-phosphorylated peptides and phosphopeptides. A bivalent cation-containing salt capable of aggregating the phosphopeptides is added to the permeate to produce a mixture containing phosphopeptide aggregates and non-phosphorylated peptides. The mixture is subjected to ultrafiltration with a membrane that retains the phosphopeptide aggregates and separates them from the non-phosphorylated peptides. The non-phosphorylated peptides have nutritive value and can be used to form compositions for providing nutrition.

Abstract: Substantially water-insoluble, crosslinked polypeptides containing 15 to 85 mole % of amino acid residues such as glutamic acid, aspartic acid, phosphoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoasparagine, or phosphoglutamine, and 15 to 85 mole % of amino acid residues such as lysine, arginine, asparagine, glutamine, serine or tyrosine, in which the degree of crosslinking is sufficient to result in a substantially water-insoluble polypeptide with the ability to absorb a 1 wt. % aqueous NaCl solution in an amount of at least 20 times the weight of the polypeptide, are useful as superabsorbents in devices such as diapers, etc. Mild alkaline hydrolysis of the crosslinked polypeptides increases their superabsorbency by two to three fold.

Abstract: Complexes which contain at least one glycosyl-phosphatidylinositol protein and at least one cholanic acid derivative of the formula I ##STR1## are suitable, inter alia, in enzyme tests and as aids in chemical reactions; where R.sup.1 is --NH--CH.sub.2 --CH.sub.2 --SO.sub.3 or --NH--CH.sub.2 --COOH, R.sup.2 is NR.sup.3 R.sup.4 or --OR.sup.5 ; R.sup.3, R.sup.4 or R.sup.5 are a hydrogen atom, (C.sub.1 -C.sub.5)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, substituted acetyl, halogen, succinyl, substituted benzyl or substituted benzoyl.

Abstract: A method of inhibiting dental calculus by applying to the teeth an oral composition containing a dental calculus inhibiting amount of one or more of the phosphopeptides SEQ.ID NO:1 to SEQ.ID NO:9, especially in the form of a zinc/phosphopeptide complex or aggregate.

Abstract: Nonphosphorylated peptides and phosphopeptides useful as alimentary products or medicaments are produced by proteolytic enzyme hydrolysis of a casein-based material. Membrane ultrafiltration is used to separate phosphopeptides which are retained by the membrane in a retentate from the nonphosphorylated peptides which pass through the membrane in an ultrafiltrate. The phosphopeptides in the retentate are disaggregated and are subjected to further membrane ultrafiltration where the phosphopeptides pass through the membrane and are separated from the enzyme. The phosphopeptides form salts, which have dietetic uses, with macroelements such as calcium and/or magnesium and/or oligoelements such as iron and zinc.

Abstract: Non-phosphorylated peptides and phosphopeptides useful as alimentary products or medicaments are produced. A hydrolyzate containing non-phosphorylated peptides and phosphopeptides is prepared by proteolytic enzyme hydrolysis of a casein-based material. The hydrolyzate is subjected to ultrafiltration with a membrane which allows peptides to pass through to produce a permeate containing the non-phosphorylated peptides and phosphopeptides. A bivalent cation-containing salt capable of aggregating the phosphopeptides is added to the permeate to produce a mixture containing phosphopeptide aggregates and non-phosphorylated peptides. The mixture is subjected to ultrafiltration with a membrane that retains the phosphopeptide aggregates and separates them from the non-phosphorylated peptides. The phosphopeptides form salts, which have dietetic uses, with macroelements such as calcium and/or magnesium and/or oligoelements such as iron and zinc.

Abstract: The present invention relates to a method for quantitatively assaying the presence of DSP toxins such as okadaic acid and dinophysistoxin-1 in marine samples. The method comprises the steps of preparing a marine extract, fractionating the prepared marine extract and selecting the extract fraction containing the toxin to be assayed. Once the desired extract fraction has been selected, a labelled substrate for protein phosphatase and at least one protein phosphatase are added to the extract in an assay. The amount of toxin present is quantitatively measured by the ability of the extract fraction to inhibit catalysis, mainly dephosphorylation, of the labelled substrate by protein phosphatases, such as phosphatase-1 (PP1) or phosphatase-2A (PP2A). Preferably, the method of the present invention is used to assay the presence of okadaic acid in marine organisms such as mussels, oysters, scallops, phytoplankton and the like.

Abstract: A method for assaying protein kinases that phosphorylate peptides such as Kemptide, such as cAMP-dependent protein kinase, or a glycogen synthase peptide, which is an excellent substrate for protein kinase C. Upon sequentially processing of reaction mixtures through tandem columns of cation and anion exchange resins improved separation of ATP from phosphorylated peptides is achieved such that radioactivity in background samples is nearly nil and the yield of phosphorylated peptides is high. This method is generally applicable to any protein kinase so long as the substrate peptide is appropriately structured such that the peptide retains a net positive charge when fully phosphorylated so that the peptide will adhere to the cation exchange resin and pass through the anion exchange resin. This method reduces labor, radioactivity, enzyme requirements, and costs of assaying protein kinases.

Abstract: A dicarbonyl halide preferably a straight-chain-alkyl dicarbonyl dihalide, may be used to activate a substrate surface of preferably polyurethane or polyamide. Optionally, an amine-end blocked polymer may be reacted with the resulting activated surface by reaction between amine and dicarbonyl halide groups. Then, a material to be covalently bonded to said surface, such as heparin, may be reacted with free amine groups bonded to the surface by a carbodiimide process or the like.

Abstract: The invention relates to a polymeric anhydride of magnesium and proteic ammonium phospholinoleate having the following distribution of components expressed in percentage of magnesium (20.1.+-.0.9%), Ammonium (10.0.+-.3.3%), Phosphate (45.2.+-.2.7%), linoleic acid (11.6.+-.4.3%), total protein (0.49.+-.0.07%) with the presence in percentage of the following aminoacids: Aspartic Acid (7.19%), Threonine (3.56%), Serine (7.56%), Glutamic Acid (8.53%), Proline (0.5%), Glycine (9.69%), Alanine (7.46%), Valine (1.0%), Methionine (4.38%), Isoleucine (2.54%), Leucine (3.03%), Thyrosine (0.5%), Phenylanine (1.0%), Histidine (2.83%), Lysine (3.56%), Tryptofan (1.3%) and Arginine (35.2%).This compound is produced from a selected line of Aspergillus sp in culture of oat schaff and bouillon at the temperature of 30.degree./35.degree. C., pH 3-4 with low aeration (10 l/m) and agitation (40 rph) restricted to the first 48 hours of the producing process.

Abstract: A micelle of an adhesion protein which naturally includes a phosphatidylinositol lipid anchor, the micelle being capable of binding multivalently to a plurality of target molecules on a cell surface; where the adhesion protein is LFA-3, the LFA-3 micelles can be administered to a patient to inhibit binding of activated T-cells to other cells.

Abstract: Casein phosphopeptide salts of calcium, magnesium or both are produced having less than 4% by weight of aromatic amino acids, greater than 8% and less than 20% by weight serine, less than 3% free amino acid content and a ratio of total calcium, magnesium and phosphorus to total nitrogen greater than 0.2. The phosphopeptides are produced by subjecting a casein material to proteolytic enzyme hydrolysis ultrafiltering the resulting hydrolyzate to produce a permeate containing phosphopeptides, adding a bivalent cation salt to the peptides to form phosphopeptide aggregates and separating by ultrafiltration the phosphopeptide aggregates from non phosphorylated peptides. The phosphopeptides obtained are useful as aliments for dietetic or therapeutic nutrition and as medicines.

Abstract: A phosphopeptide or a salt thereof the phosphopeptide having from 5 to 30 amino acids including the sequenceA-B-C-D-Ewhere A, B, C, D and E are independently phosphoserine, phosphothreonine, phosphotyrosine, phosphohistidine, glutamate and aspartate and compositions particularly compositions to teeth including same.

Abstract: This invention relates in general to a phosphoprotein product of the retinoblastoma susceptibility gene. In particular, this invention relates to a phosphoprotein ppRB.sup.110 primarily located in the cell nucleus which has a DNA binding activity. The invention also relates to the amino acid sequence of the phosphoprotein and to the specific purified anti-retinoblastoma phosphoprotein antibody. The invention further relates to a method of diagnosing retinoblastoma and other retinoblastoma gene involved cancers, treating such kind of cancers and regulating the oncogenicity of other genes.

Abstract: A method and kit are described for detecting the presence of cancers and pre-neoplastic cells that produce an oncofetal phosphoprotein having a molecular weight of approximately 60,000 and having the capacity to increase the release of ribonucleic acid from cell nuclei. The method involves detecting the presence of auto-antibodies to this oncofetal phosphoprotein in a subject suspected of suffering from a cancer or pre-neoplastic cells which produce this cancer marker protein. The kit includes purified oncofetal phosphoprotein.

Abstract: A diagnostic method for neurological and psychiatric disorders utilizes the cerebrospinal fluid incubated in the presence of 32-P labelled ATP and an appropriate protein kinase. After termination of the reaction, a sample is applied to gels for electrophoresis. Subsequent autoradiography results in a disease-specific protein pattern that can be used for diagnosis of disorders such as Alzheimer disease, Huntington disease, Parkinson disease, dystonia ataxia, schizophrenia, epilepsy brain tumors, brain irradiation, head trauma, and acute and chronic encephalitic and vascular disease.

Abstract: Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.

Abstract: A method is provided for producing an effective adjuvant response or stimulating the immune response of a warm blooded animal which comprises administering to said warm blooded animal an effective amount of a composition comprising refined detoxified endotoxin in combination with a pharmaceutically acceptable carrier.

Abstract: A casein phosphopeptide composition is prepared containing less than 4% phenylalanine, tyrosine and tryptophan, greater than 8% and less than 20% serine, a ratio of Ca+Mg+P/N.sub.T greater than 0.2, wherein N.sub.T is the total nitrogen content times 6.38, and free amino acids of less than 3%. The composition is useful as an ailment for dietetic or therapeutic nutrition or as a medicament. Salts of the phosphopeptides may be formed from macroelements such as calcium and/or magnesium and/or from oligoelements such as iron, zinc and copper. The composition is produced by proteolytic enzyme hydrolysis of a casein-based material, and using ultrafiltration and aggregration with a bivalent cation salt to isolate the phosphopeptide composition.

Abstract: It has previously been shown that the serum from patients suffering from a wide range of cancers contains a cancer marker protein having the ability to release RNA from cell nuclei. This cancer marker protein is purified by taking the protein fraction precipitating between 30% and 50% saturated aqueous ammonium sulfate solution, dialyzing a solution of the protein fraction against TMK buffer, chromatographing the dialyzed protein on a molecular sieve and isolating the fraction having a molecular weight of about 60,000; and removing albumin. Injection of the purified protein into rabbits, preparation of serum from blood of the rabbits and absorption of the sera with normal plasma fraction produces at antibody specific to the cancer marker protein and therefore useful in a radioimmunoassay or ELISA test for a wide variety of cancers.

Abstract: Nonphosphorylated peptides and phosphopeptides useful as alimentary products or medicaments are produced by proteolytic enzyme hydrolysis of a casein-based material. Ultrafiltration is used to separate phosphopeptides and nonphosphorylated peptides after hydrolysis. A bivalent cation is added to form aggregates of the phosphopeptides, and the aggregated phosphopeptides are separated from the nonphosphorylated peptides by ultrafiltration. The phosphopeptides form salts, which have dietefic uses, with macroelements such as calcium and/or magnesium and/or oligoelements such as iron and zinc.

Abstract: A glycoprotein phosphotyrosyl protein phosphatase is isolated from human tissues, such as human placental membrane. Upon membrane solubilization and extraction of the enzyme it was subjected to chromatographic purification and isolation. The analytical and biological responses of the enzyme demonstrate that it is novel and readily distinguished from other enzymes previously isolated from similar tissues. The enzyme is a dephosphorylation enzyme of membrane phosphoprotein kinases, and as such has utility as an antidiabetic agent, an antiatherosclerosis agent or an antitumor agent since certain membrane receptor kinases involved in each such biological function involve a phosphorylation mechanism for cell transformation, metabolism and growth and which, when blocked by the instant enzyme, results in a suppression or alteration of the biological function.

Abstract: PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudonomas aeruginosa infection.

Abstract: There are provided a crystalline and single rod products derivable from the Pili of Type 1 and Type 2 Neisseria gonorrhoese organisms. There are provided methods of growing said organisms to produce the maximum yield of Pili and procedures for purifying said Pili to produce said crystalline material. There are further provided methods of utilizing said Pili to determine the presence, in a system infectable by N. gonorrhoese organisms, of antibodies to the Pili of said organisms, and methods of serotyping said Pili. There is also provided a mode of utilizing said crystalline material to provide a substantial degree of immunization infection by N. gonorrhoese in mammalian systems susceptible to such infection.

Abstract: A pharmaceutical composition comprising a purified pyridine-soluble extract of a microorganism and a refined detoxified endotoxin which is effective in producing an immunological response in warm blooded animals and humans. Methods of using the composition for these purposes are also disclosed.